F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control.
Much evidence has suggested that oxidative stress (OS) may play a role in the pathogenesis of diabetic complications. However, the relationship between hyperglycemia and OS is inconsistent in diabetic clinical studies. The aim of this study was to evaluate the effect of normalization of blood glucose levels on urinary 8-epi-prostaglandin F(2alpha) (8-epi-PGF(2alpha)) excretion at the onset of type 1 diabetes. We studied 14 type 1 diabetic patients (50% males; mean age, 24.3 +/- 4.9 years) and 14 control subjects matched by age and body mass index. A 24-hour urine collection was performed to determine 8-epi-PGF(2alpha) as an integrated index of OS production at baseline, before starting insulin therapy, and 16 weeks later. Insulin treatment induced a significant reduction in glycosylated hemoglobin (HbA(1c)) (from 11.5% to 5.4% P =.0001), triglycerides (from 1.0 to 0.8 mmol/L, P =.002), and an increase in high-density lipoprotein (HDL)-cholesterol levels (from 1.1 to 1.5 nmol/L, P =.01) at week 16. This improvement in metabolic control was associated with a statistically significant reduction in 8-epi-PGF(2alpha) values (from 92.0 +/- 41.5 to 66.9 +/- 28.9 pg/mg urinary reatinine excretion, P =.015), although compared with the control group, 8-epi-PGF(2alpha) values remained higher in diabetic patients (66.9 +/- 28.9 v 39.1 +/- 13.8 pg/mg creatinine, P =.004). Enhanced OS is present in early clinical phases of type 1 diabetes, and the amelioration in metabolic control is associated with improvement in this pathogenic pathway.
Flores
Lilliam
L
Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Rodela
S
S
Abian
J
J
Clària
Joan
J
Esmatjes
E
E
D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D001786:Blood Glucose / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000276:immunology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male
D001323:Autoantibodies; D001786:Blood Glucose; D015237:Dinoprost; D028441:F2-Isoprostanes; D006442:Glycated Hemoglobin; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; C075750:8-epi-prostaglandin F2alpha